Patients
migraine
MIGRAINE
Of 892 patients randomized in the 24-week placebo-controlled period, 865 (97.0%) completed that portion of the study, enrolled in this dose-blinded extension period, and comprised the safety analysis set (eptinezumab 100 mg, 
CONSORT diagram of patient disposition.  Safety analyses were conducted in the all-patients-treated set, which included all randomized patients who received ≥ 1 infusion of double-blind study drug and had a visit in the extension period. Efficacy analyses were conducted in the full analysis set, which included all randomized patients who received ≥ 1 infusion of double-blind study drug, had a valid baseline assessment, and had ≥ 1 valid assessment of monthly migraine days in the extension period
Demographic and baseline characteristics of patients enrolled in the dose-blinded extension (efficacy analysis set)
There was a high level of compliance with the eDiary. The mean rate of missing eDiary data was ~ 10% (mean [SE]: 10.1% [0.65], 100 mg; 9.0% [0.56], 300 mg) during Weeks 25–28, and only increased to ~ 18% during Weeks 69–72 (17.5% [1.04], 100 mg; 18.3% [0.99], 300 mg). The proportion of patients with ≥ 14 days of compliance was 98.5% during Weeks 25–28 and gradually declined to 92.9% at Weeks 69–72.